EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access

Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation

Siddharth M Patel iD, Eugene Braunwald iD, Jan Steffel iD, Giuseppe Boriani iD, Michael G Palazzolo iD, Elliott M Antman iD, Erin A Bohula iD, Anthony P Carnicelli iD, Stuart J Connolly iD, John W Eikelboom iD, Baris Gencer iD, Christopher B Granger iD und 6 weitere

Circulation · 19.03.2024 · 149 (12) · 932-943

DOI: 10.1161/circulationaha.123.066279 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Circulation, erschienen am 19.03.2024. Verfasst von Siddharth M Patel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (S.M.P., E.B., M.G.P., E.M.A., E…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The efficacy and safety of non–vitamin-K antagonist oral anticoagulants (NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain uncertain. METHODS: We analyzed data from COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation), which pooled patient-level data from the 4 pivotal randomized trials of NOAC versus warfarin in patients with atrial fibrillation. The primary efficacy and safety outcomes were stroke or systemic embolic events (stroke/SEE) and major bleeding, respectively; secondary outcomes were ischemic stroke/SEE, intracranial hemorrhage, death, and the net clinical outcome (stroke/SEE, major bleeding, or death). Each outcome was examined across BMI and BW. Because few patients had a BMI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeHumansWarfarinAnticoagulantsBody Mass IndexAdministration, OralRandomized Controlled Trials as TopicHemorrhageBody WeightTreatment Outcome

Stichwörter der Autor:innen

anticoagulationatrial fibrillationclinical trialmeta-analysisobesitystrokewarfarin

Substanzen

WarfarinAnticoagulants

Autor:innen und Institutionen

  • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (S.M.P., E.B., M.G.P., E.M.A., E.A.B., D.A.M., C.T.R., R.P.G.).
  • Hirslanden Clinic, Zurich, Switzerland and University of Zurich, Switzerland (J.S.).
  • Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Italy (G.B.).
  • Cardiology Division, Department of Internal Medicine, Medical University of South Carolina, Charleston (A.P.C.).
  • Department of Medicine, McMaster University, Hamilton, Canada (S.J.C., J.W.E.).
  • Division of Cardiology, Geneva University Hospitals, Switzerland (B.G.).

ORCID-Profile: Siddharth M Patel, Eugene Braunwald, Jan Steffel, Giuseppe Boriani, Michael G Palazzolo, Elliott M Antman, Erin A Bohula, Anthony P Carnicelli, Stuart J Connolly, John W Eikelboom, Baris Gencer, Christopher B Granger, David A Morrow, Manesh R Patel, Lars Wallentin, Christian T Ruff, Robert P Giugliano

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Patel, S. M., Braunwald, E., Steffel, J., Boriani, G., Palazzolo, M. G., Antman, E. M., Bohula, E. A., Carnicelli, A. P., Connolly, S. J., Eikelboom, J. W., Gencer, B., Granger, C. B., Morrow, D. A., Patel, M. R., Wallentin, L., Ruff, C. T., Giugliano, R. P., & COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investi… (2024). Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. Circulation, 149(12), 932-943. https://doi.org/10.1161/circulationaha.123.066279

Vancouver

Patel SM, Braunwald E, Steffel J, Boriani G, Palazzolo MG, Antman EM, et al. Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. Circulation. 2024;149(12):932-943. doi:10.1161/circulationaha.123.066279

BibTeX
@article{Patel2024,
  author = {Patel, Siddharth M and Braunwald, Eugene and Steffel, Jan and Boriani, Giuseppe and Palazzolo, Michael G and Antman, Elliott M and Bohula, Erin A and Carnicelli, Anthony P and Connolly, Stuart J and Eikelboom, John W and Gencer, Baris and Granger, Christopher B and Morrow, David A and Patel, Manesh R and Wallentin, Lars and Ruff, Christian T and Giugliano, Robert P and COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investi…, COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investi…},
  title = {Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation},
  journal = {Circulation},
  year = {2024},
  volume = {149},
  number = {12},
  pages = {932--943},
  doi = {10.1161/circulationaha.123.066279}
}
Kostenlos starten →